Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News

Icon

First Digital Health Formulary by Express Scripts includes CBT-based programs to treat depression, anxiety and insomnia

Source: Express Scripts

_____

Express Scripts Launch­es First Dig­i­tal Health For­mu­la­ry for Apps & Devices (HIT Con­sul­tant):

Start­ing in Jan­u­ary 2020, Express Scripts Dig­i­tal Health For­mu­la­ry will ini­tial­ly include 15 solu­tions for remote mon­i­tor­ing ser­vices and dig­i­tal ther­a­peu­tics that aid in the man­age­ment of eight of the country’s most com­mon chron­ic con­di­tions: dia­betes, pre­di­a­betes, hyper­ten­sion, asth­ma, pul­monary dis­ease, depres­sion, anx­i­ety, and insom­nia Read the rest of this entry »

On Awe, Healthy Eating, Mental Health, Ethical Neurotech, and more

_____

Time to wrap-up anoth­er very active month with our Sharp­Brains e‑newsletter sum­ma­riz­ing excit­ing devel­op­ments in brain research, health­care and tech­nol­o­gy — plus a cou­ple fun brain teasers to spark curios­i­ty and inno­va­tion 🙂

New brain research:

New thinking about brain & mental health:

Emerging neurotech and digital brain health:

Finally, a couple fun brain teasers:

 

Have a excel­lent Hal­loween…

 

The Sharp­Brains Team

Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse

_______________

As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­mote arrange­ments? (MM&M):

San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed a co-pro­mo­tion deal.

Since the Sandoz/Pear pact was wide­ly seen as a lit­mus test of sorts for pharma’s role in help­ing dis­trib­ute this nascent tech­nol­o­gy, the com­mer­cial break-up rais­es ques­tions about the via­bil­i­ty of such part­ner­ships going for­ward. It also high­lights the par­ties’ some­times con­flict­ing pri­or­i­ties: Read the rest of this entry »

A call to action: We need the right incentives to guide ethical innovation in neurotech and healthcare

_______________

Ana Maiques, CEO and founder of neu­rotech com­pa­ny Neu­ro­electrics, writes up a com­pelling case in her recent arti­cle, sum­ma­rized thus:

I strong­ly believe that Neu­rotech entre­pre­neurs can not afford not to be involved in neu­roethics. It is sim­ply not an option any­more.”

I share that belief and would like to take it one step fur­ther:

I strong­ly believe that health­care prac­ti­tion­ers, researchers, exec­u­tives and reg­u­la­tors can not afford not to be involved in neu­roethics. It is sim­ply not an option any­more.”

Read the rest of this entry »

Bayer to support 11 digital health startups, 5 of which are developing behavioral/ cognitive/ mental health solutions

_______________

Bay­er inks deals with eleven star­tups under G4A Dig­i­tal Health Part­ner­ships pro­gram (press release):

Bay­er announced today that the com­pa­ny has signed col­lab­o­ra­tion agree­ments with eleven dig­i­tal health star­tups. As part of the pro­gram, Bay­er will sup­port these start­up com­pa­nies aim­ing for longer-term col­lab­o­ra­tions to dri­ve for­ward the devel­op­ment of spe­cif­ic dig­i­tal solu­tions to improve patients’ health Read the rest of this entry »

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Search in our archives

Follow us and Engage via…

twitter_logo_header
RSS Feed

Watch All Recordings Now (40+ Speakers, 12+ Hours)

Enter Your Email to receive Sharp­Brains free, monthly eNewslet­ter:

Join more than 50,000 Sub­scribers and stay informed and engaged.